Bioequivalence study of 4 mg/5 mL Methylprednisolone Suspensions, Manufactured by PT. Lapi Laboratories (Lameson®) In Comparison with The Innovator’s 4 mg Tablets (Medrol®) Manufactured by Pfizer Italia S.r.l., Ascoli, Italy, Imported by PT. Pfizer Indonesia, Jakarta, Indonesia
Tahapan Penelitian : Complete
Sponsor:
PT Lapi Laboratories
Mitra Pelaksana:
Econolab
No Registry
INA-DKHR6TX
Tanggal Input Registry : 07-02-2024
| Tracking Information | |
|---|---|
| Tanggal Antisipasi Studi | 08-02-2019 |
| Outcome Primer | AUC0-t and Cmax |
| Outcome Skunder | AUC0-t, Tmax, T1/2 |
| Descriptive Information | |
| Judul Penelitian Popular | Bioequivalence study of 4 mg/5 mL Methylprednisolone Suspensions, Manufactured by PT. Lapi Laboratories (Lameson®) In Comparison with The Innovator’s 4 mg Tablets (Medrol®) Manufactured by Pfizer Italia S.r.l., Ascoli, Italy, Imported by PT. Pfizer Indonesia, Jakarta, Indonesia |
| Judul Penelitian Ilmiah | Bioequivalence study of 4 mg/5 mL Methylprednisolone Suspensions, Manufactured by PT. Lapi Laboratories (Lameson®) In Comparison with The Innovator’s 4 mg Tablets (Medrol®) Manufactured by Pfizer Italia S.r.l., Ascoli, Italy, Imported by PT. Pfizer Indonesia, Jakarta, Indonesia |
| Jenis Penelitian | Interventional |
| Intervensi | Single dose of 10 mL of 4 mg/5 mL Methylprednisolone Suspensions (Lameson®), Manufactured by PT Lapi Laboratories |
| Jumlah Subyek Penelitian | 14 |
| Recruitment Information | |
| Eligibility Criteria | Inclusion Criteria: Healthy male/female subjects determined by the medical screening assessments; Aged 18-55 years of age; Body mass index is in the range of 18-25 kg/m²; Systolic blood pressure:100-120 mmHg; Diastolic blood pressure: 60-80 mmHg; Pulse rate 60-90 bpm; Normal ECG; Able to communicate well with the investigators and sign an informed consent; Clinical laboratory results have to be within normal range, if those results are in abnormal range, the physician was justified the result to include subject to the study.Exclusion Criteria: Pregnant or lactating women (urinary pregnancy test were applied to female subjects when screening and just before taking the test or innovator drug); Known hypersensitivity or contraindication to the study drug; intake of any prescription drug or non-prescription drug/food supplement/herbal medicine within 7 days of this study’s first dosing day; History of any bleeding or coagulation disorders; Any surgical or medical condition (present or history) which might significantly alters the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal diseases including gastric or duodenal ulcers or history of gastric surgery; A donation or loss of 300 mL (or more) of blood within 3 months before this study’s first dosing day; A positive Hepatitis B surface antigen (HBsAg), HCV, HIV test result; History of drug or alcohol abuse within 12 months prior to this study; Heavy Smoker (more than 10 cigarettes a day); Clinically have significant bleeding within 3 months prior to the study; Participation in a previous study within 3 months of this study’s first dosing day. |
| Administrative Information | |
| Nomor Persetujuan Etik | 0739/UN2.F1/ETIK/2018 |
| Nomor Persetujuan Material Transfer Agreement | Not applicable |
| Nomor Persetujuan Pelaksanaan Uji Klinik | PPUK/PPUB number |
| Other Study ID Numbers | PRO-224/18/ECL |
| Contact Person | Ni Made Dwi Wulandari |